33. Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone at physiological doses modulates immune function in postmenopausal women. Am J Obstet Gynecol. 1993 Dec;169(6):1536-9. 94. Valenti G. Andrenopause: an imbalance between dehydroepiandrosterone (DHEA) and cortisol secretion. J Endocrinol Invest. 2002 25(10 suppl):29- 35.
111. Lubet RA, Gordon GB, Prough RA, et al. Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes and lack of effects on levels of Ha-Ras mutations. 1998 Mar 1;58(5):921-6. DHEA is a “legal” supplement ingredient, not a controlled substance. Nevertheless, the World Anti-Doping Agency (WADA) bans its use in sport. However, DHEA is not prohibited by the DoD or any of the service branches. 24.
Genazzani AR, Inglese S, Lombardi I, et al. Long-term low-dose dehydroepiandrosterone replacement therapy in aging men with partial androgen deficiency. Homme vieillissant. 2004 Jun;7(2):133-43. 70. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. L’effet de six mois de traitement avec une dose quotidienne de 100 mg de déhydroépiandrostérone (DHEA) sur les stéroïdes sexuels circulants, la composition corporelle et la force musculaire chez les hommes et les femmes avancés. Clin endocrinol (Oxf). 1998 Oct;49(4):421-32. 112.
Perkins SN, Hursting SD, Haines DC, et coll. Chemoprevention of spontaneous tumorigenesis in nullizygots p53-deficient mice by dehydroepiandrosterone and its analogous 16alpha-fluoro-5-androstene-17-one. Carcinogénèse. 1997 Mai;18(5):989-94. 21. Michael A, Jenaway A, Paykel ES, Herbert J. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol Psychiatrie. 15 novembre 2000;48(10):989-95. 60. Ayhan S, Markal N, Siemionov K, Araneo B, Siemionov M. Effect of subspinatus treatment of dehydroepiandrosterone on the healing of repaired transected nerves using the spinous sleeve technique.
Microsurgery. 2003;23(1):49-55. 109. Simile M, Pascale RM, De Miglio MR, et al. Inhibition of growth and progression of persistent liver nodules by dehydroepiandrosterone in experimental rat liver carcinogenesis. Int J cancer. 1995 Jul 17;62(2):210-5. 130. Schulz S, Klann RC, Schonfeld S, Nyce JW.
Mechanisms of cell growth inhibition and cell cycle arrest in human colon adenocarcinoma cells by dehydroepiandrosterone: role of isoprenoid biosynthesis. 1992 Mar 1;52(5):1372-6. 61. Nordmark G, Bengtsson C, Larsson A, et al. Effects of dehydroepiandrosterone supplements on health-related quality of life in glucocorticoid-treated patients with systemic lupus erythematosus. Autoimmunity. 2005 Nov;38(7):531-40. 27. Moriyama Y, Yasue H, Yoshimura M, et al. Plasma levels of dehydroepiandrosterone sulfate are decreased in proportion to severity in patients with chronic heart failure. J Clin Endocrinol Metab.
2000 May;85(5):1834-40. 68. Martina V, Benso A, Gigliardi VR, et al. Short-term treatment with dehydroepiandrosterone increases platelet GMP production in older male subjects. Endocrine clin (Oxf). 2006 Mar;64(3):260-4. 5. Mazat L, Lafont S, Berr C, et al. Prospective measurements of dehydroepiandrosterone sulfate in a cohort of older subjects: relationship to sex, subjective health, smoking habits and 10-year mortality.
Proc Natl Acad Sci USA. 2001 Jul 3;98(14):8145-50. 83. Young AH, Gallagher P, Porter RJ. Increased cortisol-dehydroepiandrosterone ratio in depressed patients without medication. Am J Psychiatry. 2002 Jul;159(7):1237-9. 143. Huot RI, Shain SA. Differential metabolism of dehydroepiandrosterone sulfate and estrogen conjugates by normal or malignant rat prostate cells AXC/SSh and effects of these steroidal conjugates on cancer cell proliferation in vitro. J Biochem steroid. 1988 Jun;29(6):617-21.
66. Alwardt CM, Yu Q, Brooks HL, et al. Comparative effects of dehydroepiandrosterone sulfate on ventricular diastolic function in young and older female mice. Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R251-6. 110. Green JE, Shibata MA, Shibata E, et al. 2-difluoromethylornithine and dehydroepiandrosterone inhibit breast tumor progression, but not the initiation of breast or prostate tumors in transgenic C3(1)/SV40 T/t antigens. 2001 Oct 15;61(20):7449-55. 16. Beishuizen A, Thijs LG, Vermes I. Decreasing Dehydroepiandrosterone sulfate levels in serious critical diseases: a sign of adrenal reserve depletion? Crit Care.
2002 Oct;6(5):434-8. 30. Williams JR. The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system and aging. Lipid. 2000 Mar;35(3):325-31. 93. Meno-Tetang GM, Blum RA, Schwartz KE, Jusko WJ. Effects of oral prasteron (dehydroepiandrosterone) on the single-dose pharmacokinetics of oral suppression of prednisone and cortisol in normal women. J Clin Pharmacol. 2001 Nov;41(11):1195-205. A bill has been introduced in Congress that would classify DHEA as an “anabolic steroid drug,” making it illegal for Americans.
48. Yang S, Fu Z, Wang F, Cao Y, Han R. Anti-mutagenicity activity of dehydroepiandrosterone. Zhonghua Zhong Liu Za Zhi. 2002 Mar;24(2):137-40. 49. Yoshida S, Honda A, Matsuzaki Y, et al.